@article{ee63bb532439432c851f496b8bf88fff,
title = "Mantle cell lymphoma: minimal residual disease outcomes",
author = "Vose, {Julie M.}",
note = "Funding Information: I report honoraria from AbbVie, Epizyme, Vaniam Group, Janssen/Pharmacyclics, Kite Pharma, Acerta/AstraZeneca, Verastem, Miltenyi Biotec, Loxo, Allogene, Wugene, Celgene, Roche, Genentech, Karyopharm, and Morphosis; and institutional research funding from Acerta/Astra Zeneca, Celgene/Bristol-Myers Squibb, Incyte Corp, Kite Pharma, Novartis, Seattle Genetics, Loxo, and Epizyme.",
year = "2020",
month = nov,
doi = "10.1016/S2352-3026(20)30274-X",
language = "English (US)",
volume = "7",
pages = "e775--e776",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "11",
}